content_image/10254.jpg content_image/10255.jpg content_image/10256.jpg content_image/10257.jpg content_image/10258.jpg content_image/10259.jpg content_image/10260.jpg content_image/10262.jpg content_image/10261.jpg
The preceding pages have discussed Allergan’s current research and development projects and the patients our therapeutics help. As our current product lines demonstrate, we have a long history of identifying unmet medical needs and dedicating our discovery efforts toward improving patients’ lives. 

<img src='content_image/10254.jpg'>

<img src='content_image/10255.jpg'>

<img src='content_image/10256.jpg'>

<img src='content_image/10257.jpg'>

<img src='content_image/10258.jpg'>

<img src='content_image/10259.jpg'>

<img src='content_image/10260.jpg'>

## OPHTHALMOLOGY 

## ACULAR (ketorolac tromethamine ophthalmic solution 0.5%) 

The No. 1 non-steroidal anti-inflammatory (NSAID) worldwide and used for a range of conditions including ocular allergy, photophobia, post-surgical ocular pain and inflammation. 

## ACULAR LS (ketorolac tromethamine ophthalmic solution 0.4%) 

Specially formulated to reduce burning and stinging following corneal refractive surgery, ACULAR LS delivers the proven NSAID performance and provides post surgical patients with a comfortable recovery. 

## ALOCRIL (nedocromil sodium 2%) 

A fast acting mast cell stabilizer approved to treat the itch associ- ated with ocular allergy. 

## ALPHAGAN (brimonidine tartrate ophthalmic solution 0.2%) 

The first alpha-2 agonist approved for the long-term treatment of elevated intraocular pressure (IOP) in patients with glaucoma and ocular hypertension. ALPHAGAN is the second largest product in the glaucoma market worldwide. 

## ALPHAGAN P (brimonidine tartrate ophthalmic solution 0.15%) 

Preserved with PURITE: A formulation containing brimonidine tartrate, a relatively selective alpha-2 agonist, which is the same active ingredient in ALPHAGAN. ALPHAGAN P is indicated for the lowering of IOP and is comparable in efficacy to ALPHAGAN with lower rates of ocular allergy. 

## ELESTAT/RELESTAT (epinastine ophthalmic solution 0.05%) 

A topical antihistamine with mast cell stabilizing activity for the prevention of itching associated with allergic conjunctivitis. The compound inhibits binding to both H1 and H2 histamine receptors, to prevent recruitment and activation of pro-inflammatory mediators that can trigger and exacerbate the ocular allergic response. 

## LUMIGAN (bimatoprost ophthalmic solution 0.03%) 

The first synthetic prostamide analog and an important component in the Company’s growing position as a leader in glaucoma management. In the United States, it is indicated for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension who are intolerant of other IOP-lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measures over time) to another IOP-lowering medication. 

<img src='content_image/10262.jpg'>

<img src='content_image/10261.jpg'>

## OCUFLOX (ofloxacin ophthalmic solution 0.3%) 

Indicated for use in bacterial conjunctivitis and corneal ulcers due to susceptible bacteria and the No.1 anti-infective prescribed by ophthalmologists in the United States (marketed as EXOCIN in Europe and OFLOX in Latin America). 

## REFRESH / ARTIFICIAL TEARS 

Artificial tear products for various needs led by the REFRESH brand which includes: REFRESH PLUS, the No.1 unit dose product worldwide; REFRESH TEARS, the No. 1 multi-dose product in the United States; REFRESH P.M., for overnight relief of dry eye; REFRESH CONTACTS, relief from dryness and irritation for contact lens wearers; REFRESH LIQUIGEL, a unique extra strength formula containing one of the most effective lubricant and preservative systems, combining the strength of a gel with the convenience of a liquid eye drop; and REFRESH ENDURA, the first lubricant eye drop for dry eye that treats all three layers of the tear film. Additionally, Allergan markets CELLUVISC, the product most often recommended for severe dry eye. Other products marketed throughout the world include the lubricants LIQUIFILM, CELLUFRESH, LACRI-LUBE, and the decongestant LERIN. 

## RESTASIS (cyclosporine ophthalmic emulsion 0.05%) 

The first and only treatment for increasing tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation. RESTASIS is the only therapeutic option on the market for people with dry eye disease that goes beyond providing temporary relief for the dryness and also treats the underlying cause of the condition – ocular inflammation. 

## ZYMAR (gatifloxacin ophthalmic solution 0.3%) 

The first FDA-approved fourth-generation topical fluoroquinolone indicated for the treatment of bacterial conjunctivitis due to susceptible bacteria, ZYMAR represents a leading advancement in the eye care community in countering emerging antimicrobial resistance. Among ophthalmologists, ZYMAR is the No. 1 pre- scribed fluoroquinolone due to its broad-spectrum activity and optimal formulation. 

